Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Leans On FDA, NIH To Put More Women In Clinical Trials

This article was originally published in The Gray Sheet

Executive Summary

There was a significant focus on putting more women in clinical trials on Capitol Hill on April 30, when 14 female Senators sent a letter to FDA, calling for an action plan to spur greater subgroup, especially female, participation in clinical trials, while a group of 10 Democrats asked GAO to examine what NIH is doing to meet the same goals.

You may also be interested in...

Biotronik Starts First ICD Study Designed To Measure Sex-Specific Outcomes

BIO-LIBRA will study Biotronik ICDs and CRT-D devices in about 1,000 patients with non-ischemic cardiomyopathy. The investigators expect at least 40% of the subjects in BIO-LIBRA to be women.

Products Lacking Good Subgroup Data Shouldn’t Be Approved, Patient, Medical Groups Tell FDA

FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts